Business
Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian
WHIPPANY, N.J., April 29, 2026--Bayer today announced that a broad set of data from its stroke franchise will be presented at the 2026 European Stroke Organisation Conference (ESOC), including new late-breaking analyses from its global, landmark Phase III OCEANIC-STROKE study of asundexian, an investigational oral Factor XIa inhibitor. In total, 13 abstracts will be presented, including four OCEANIC-STROKE sub-analyses. Additionally, Bayer will present nine real-world analyses examining stroke o
About this update from Bayer Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/162e4d72af9d22795f916fab5010f57c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IGRxgqYuoVJ_COzdUThWpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNQ--/https://media.zenfs.com/en/business-wire.com/162e4d72af9d22795f916fab5010f57c","width":400,"height":400}},"lazy":false},{"type":"text","content":"KEY FACTS","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Two late-breaking presentations from the landmark OCEANIC-STROKE study will provide new insights into ischemic strokes that occurred during the trial, as well as the net clinical benefit analysis","length":195,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Additional data to be presented at ESOC 2026 include analyses of intracranial hemorrhage and predictors of recurrent ischemic stroke from OCEANIC-STROKE","length":152,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Nine real-world analyses to provide insights into stroke care and patient outcomes","length":82,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":429,"olType":false},{"type":"text","content":"WHAT’S HAPPENING","length":16,"tagName":"p"},{"type":"text","content":"WHIPPANY, N.J., April 29, 2026--(BUSINESS WIRE)--Bayer today announced that a broad set of data from its stroke franchise will be presented at the 2026 European Stroke Organisation Conference (ESOC), including new late-breaking analyses from its global, landmark Phase III OCEANIC-STROKE study of asundexian, an investigational oral Factor XIa inhibitor. In total, 13 abstracts will be presented, including four OCEANIC-STROKE sub-analyses. Additionally, Bayer will present nine real-world analyses examining stroke outcomes and patterns of care. The congress takes place May 6-8 in Maastricht, the Netherlands.","length":611,"tagName":"p"},{"type":"text","content":"WHY THIS MATTERS","length":16,"tagName":"p"},{"type":"text","content":"Two late-breaking analyses from the Phase III OCEANIC-STROKE study will provide additional depth to the primary efficacy and safety results.","length":140,"tagName":"p"},{"type":"text","content":"BAYER EXECUTIVE COMMENT","length":23,"tagName":"p"...